Location：Home/News/Company NewsOn the afternoon of September 25, 2023, Zhangjiang Life Science International Innovation Summit took place at Zhangjiang Science Hall. KeChow Pharma was honored with the title of “2023 Zhangjiang Life Science Industry New Prominent”.
The summit was guided by Shanghai Municipal Commission of Economy and Information, Shanghai Technology Innovation Center Construction Office, and the People’s Government of Pudong New Area. It was supported by Pudong New Area Commission of Science, Technology and Economy, and Shanghai Zhangjiang Science City Construction Management Office, and hosted by Zhangjiang Group.
Dr. Tian Hongqi, Founder and Chairman of KeChow Pharma, stated: “We are honored to receive the “2023 Zhangjiang Life Science Industry New Prominent” award. This recognition motivates us to work even harder and accelerate our efforts to consistently deliver high-quality, innovative drugs to serve patients worldwide.”
About KeChow Pharma
KeChow Pharma is dedicated to developing innovative treatments for tumors, free radical-related diseases, and other therapeutic areas. Its pipeline includes MEK inhibitor, chemoprotective agents, KRASG12C inhibitor, pan-RAF inhibitor, and multiple other tumor-targeted inhibitors. Notably, its MEK inhibitor, Tunlametinib (HL-085), has submitted a new drug application in China and is included in the CSCO guidelines. Another novel drug, a chemoprotective agent, demonstrates superior efficacy and safety compared to current clinical counterparts. All research efforts aim to address unmet clinical needs globally and within China by developing original small molecule drugs with “best-in-class” potential, bridging domestic gaps and fulfilling scientific aspirations to enhance quality of life.
